ClinicalTrials.gg

Program

LY4005130

A development code.

In Eli Lilly's pipeline, XCL1/XCL2 neutralizing antibody. Its studies are mostly in Alopecia Areata · Vitiligo, led by Eli Lilly.

Furthest: phase 2, since Apr 9, 20263 company-led studies, 2 open or runningNext primary completion: May 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly32 open or runningphase 2since Apr 9, 2026Nov 14, 2024May 2027phase 2 · NCT07533019
  • Named in Eli Lilly’s own pipeline as XCL1/2 Neutralizing Antibody, phase 2, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 14, 2024First study: phase 1 study in HealthyFirst studyNCT06690996 · 110 enrolled · United States
  2. Apr 9, 20262 phase 2 studiesPhase 2 reachedNCT07533019, NCT07533006

Ahead

  1. May 2027Primary completion: phase 2 study in VitiligoNCT07533019
  2. Jun 2027Primary completion: phase 2 study in Alopecia AreataNCT07533006

TargetBeta

“XCL1/XCL2 neutralizing antibody”the company's pipeline, read by Claude · source

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07533019Vitiligo · United States, Belgium, Canada and more2RecruitingMay 202766
NCT07533006Alopecia Areata · United States, Canada, China and more2RecruitingJun 202765
NCT06690996Healthy · United States1CompletedApr 28, 2026110

How it is read

Names in the registry

  • “LY4005130”, 4 entries

Codes read as this program: LY4005130.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.